PRFX Stock Overview
A clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
PainReform Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.16 |
| 52 Week High | US$80.64 |
| 52 Week Low | US$1.73 |
| Beta | 0.74 |
| 1 Month Change | 99.29% |
| 3 Month Change | 261.82% |
| 1 Year Change | -81.62% |
| 3 Year Change | -97.08% |
| 5 Year Change | n/a |
| Change since IPO | -99.31% |
Recent News & Updates
Shareholder Returns
| PRFX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 282.2% | -2.0% | -3.5% |
| 1Y | -81.6% | 7.6% | 22.1% |
Return vs Industry: PRFX underperformed the US Pharmaceuticals industry which returned 7.6% over the past year.
Return vs Market: PRFX underperformed the US Market which returned 22.1% over the past year.
Price Volatility
| PRFX volatility | |
|---|---|
| PRFX Average Weekly Movement | 127.2% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PRFX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PRFX's weekly volatility has increased from 66% to 127% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 7 | Ehud Geller | www.painreform.com |
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
PainReform Ltd. Fundamentals Summary
| PRFX fundamental statistics | |
|---|---|
| Market cap | US$1.21m |
| Earnings (TTM) | -US$17.67m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs PRFX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRFX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.67m |
| Earnings | -US$17.67m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -31.75 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PRFX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 05:59 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PainReform Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason McCarthy | Maxim Group |
| Nazibur Rahman | Maxim Group |